

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

CIN No.: L51909GJ2014PLC078227

GST No.: 24AAECT8906D1ZG

Date: 15th July, 2023

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai – 400001.

Stock ID: TLL Scrip Code: 543616

Sub: Outcome of Board Meeting held on 15.07.2023

We wish to inform you that the Board of Directors, at their meeting held on today i.e. Saturday, 15th July, 2023, has transacted, approved and taken on record the following items of business;

1. Approval of Un-Audited Standalone and Consolidated Financial Results:

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2023. (The copy of Un-Audited Standalone & Consolidated Financial results along with Limited Review Report of Auditors thereon is attached herewith as (Annexure-A).

Further, pursuant to the provisions of Regulation 47 of the SEBI Listing Regulations, an extract of the aforementioned Financial Results would be published in the newspapers in accordance with the SEBI Listing Regulations, and the same will be made available on the Company's website at http://www.tridentlifeline.com/.

2. Appointment of Internal Auditor of the Company for Financial Year 2023-2024:

The Board of Directors has inter alia approved the Appointment of DAC & Co. Chartered Accountants, (FRN: 137035W, PR: 014160) as an Internal Auditor of the Company for the Financial Year 2023-2024.

Pursuant to provisions of Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, the disclosure as required is provided in (Annexure-B).

3. Take note of Resignation of Mr. Dhavl Vimal Shah (DIN: 06366475), Independent Director of the Company.

Mr. Dhavl V Shah (DIN: 06366475), Independent Director of the Company has vided his resignation letter dated 15.07.2023 resigned from the Board of Directors of the Company and all other committees of the Company in which he is member with immediate effect.

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2451274, 2451284 Email: info@tridentlifeline.com Web: www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2490224, 2490225



GST No.: 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Further, the Company has received confirmation from Mr. Dhavl Vimal Shah that there are no other material reasons for his resignation other than those mentioned in his resignation letter enclosed as (Annexure-C).

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as (Annexure-B).

4. Approved the acquisition of majority stake (i.e. 51%) in TLL Herbal Limited ("TLL Herbal, making it Subsidiary of the Company.

The Board of Directors of the Company has approved the acquisition of majority stake (51%) in TLL Herbal Limited ("TLL Herbal") (CIN: U24299GJ2019PLC111182) from the existing shareholders of TLL Herbal, making it Subsidiary of the Company.

Further, the information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith (Annexure-D).

5. Take note of various compliances made during the quarter ended June 30, 2023.

The Board Meeting commenced at 05:30 p.m. and concluded at 07:0.0 p.M.

You are requested to kindly take the note of above on records.

Thanking You,

Yours Faithfully For **Trident Lifeline Limited**,

Kunal Amrishbhai Chauhan Company Secretary & Compliance Officer

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2451274, 2451284 Email: info@tridentlifeline.com Web: www.tridentlifeline.com Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2490224, 2490225



A Bafna & Associates

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

Limited Review Report on unaudited standalone financial results of Trident Lifeline Limited for the quarter ended 30th June, 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors

TRIDENT LIFELINE LIMITED

2nd Floor, Shop-2004, North Extension, Falsawadi, Begumpura, Sahara Darwaja, Surat, Gujarat - 395003

- 1. We have reviewed the accompanying statement of Unaudited Standalone Financial result of TRIDENT LIFELINE LIMITED for the quarter ended on 30th June, 2023. This Statement is responsibility of the Company's Management and has been approved by its Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2. We conducted our review of the statement in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015) including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Bafna & Associates **Chartered Accountants** (Firm Reg. No:- 121901W)

D. P. Choxii

CA Dipesh Choksi Partner

M. NO. 128674

ICAI UDIN NO.:- 23128674BGZROX9689

Place: Surat

Date: 15/07/2023

Notes to Financial Results

- 1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
- 2. The above Financial Results of the company for the period ended as on 30th June, 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 15th, 2023.
- 3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.



TRIDENT LIFELINE LIMITED

[CIN : L51909GJ2014PLC078227]

2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat, Gujarat-395003

| Standalone Profit And Loss Statement of Unaudited Fina | | The state of the s | | mount In Lac | |
|------------------------------------------------------------------------------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------|--|
| | Quarter Ended | | | Year Ended | |
| Particulars | 30.06.2023 Unaudited (CY Q1) | 31.03.2023 Audited (PY Q4) | 30.06.2022 Unaudited (PY Q1) | 31.03.2023 Audited FY 2022-23 | |
| I. Revenue From Operations | | | | | |
| Net Sales/Income From Operations (Net of Taxes) | 864.26 | 845.83 | 597.20 | 3169.2 | |
| Other Income | 32.87 | 63.23 | 0.88 | 115.3 | |
| TOTAL INCOME | 897.14 | 909.06 | 598.08 | 3284.5 | |
| II. EXPENSES | | | | | |
| Cost of Materials Consumed | 407.95 | 354.64 | 272.95 | 1218.5 | |
| Purchase of Stock-in-Trade | 119.87 | 277.19 | 324.86 | 1092.9 | |
| Changes in Inventories of Finished Goods, | | | | | |
| Work-In-Progress and Stock-In-Trade | 13.18 | -138.02 | -210.11 | -289.4 | |
| Employment Benefit Expenses | 47.84 | 51.18 | 32.05 | 161.0 | |
| Financial Costs | 09.88 | 15.41 | 08.20 | 46.5 | |
| Depreciation and Amortization Expenses | 13.34 | 11.76 | 09.12 | 36.4 | |
| Other Expenses | 99.00 | 105.79 | 90.96 | 361.0 | |
| TOTAL EXPENSES | 711.06 | 677.96 | 528.03 | 2627.2 | |
| III. Profit Before Exceptional and Extraordinary Items and Tax | 186.08 | 231.10 | 70.05 | /F7 3/ | |
| IV. Exceptional Items | - | 231.10 | 70.05 | 657.3 | |
| V. Profit Before Extraordinary Items and Tax | 186.08 | 231.10 | 70.05 | , 4E7.3 | |
| VI. Extraordinary Items | | 231.10 | 70.03 | 657.3 | |
| VII. Profit Before Tax | 186.08 | 231.10 | 70.05 | 657.3 | |
| III. Tax Expense : | | | 70.05 | 037.31 | |
| (1) Current Tax | -45.78 | -4.24 | - 1 | -54.0 | |
| (2) MAT Credit | - | - | - | 31.0 | |
| (3) Excess Tax Provision of Earlier Year | - | - | - | 49.80 | |
| (4) Deferred Tax | - | -29.43 | | -51.94 | |
| IX. Net Profit/(Loss) for the Period | 140.30 | 197.44 | 70.05 | 601.20 | |
| X. Paid Up Equity Share Capital (FV:- Rs. 10/- each) XI. Earning Per Equity Share: | 1149.92 | 1149.92 | 800.00 | 1149.92 | |
| (1) Basic- Not Annualized | 01.22 | 01.72 | 0.88 | 06.22 | |
| (2) Diluted- Not Annualized | 01.22 | 01.72 | 0.88 | 06.22 | |

For And On Behalf Of The Board TRIDENT LIFELINE LIMITED

Place : Surat

Date: 15th July, 2023

Executive Director Hardik Desai (DIN No: 01358227) Whole Time Director &

CFO

Mayurkumar Gajera (DIN No: 08629139)



Notes to Financial Results

- The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
- The above Financial Results of the company for the period ended as on 30th June, 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 15th, 2023.
- 3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.



A Bafna & Associates

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

Independent Auditor's Review Report on unaudited consolidated financial results of Trident Lifeline Limited for the quarter ended on 30th June, 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of

TRIDENT LIFELINE LIMITED 2nd Floor, Shop-2004, North Extension, Falsawadi, Begumpura, Sahara Darwaja, Surat, Gujarat - 395003

- 1. We have reviewed the accompanying statement of unaudited consolidated financial result of TRIDENT LIFELINE LIMITED and its subsidiary TNS PHARMA PRIVATE LIMITED (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended on 30th June, 2023 and for the period from 01st April, 2023 to 30th June, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended on 30th June, 2023 and the corresponding period from 01st April, 2023 to 30th June, 2023, as reported in these financial results have been approved by the Parent's Board of Directors.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the following entities:
 - a) M/s. Trident Lifeline Limited (The parent company)
 - b) M/s. TNS Pharma Private Limited (The subsidiary company)
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A Bafna & Associates Chartered Accountants (Firm Reg. No:- 121901W)

SURAT FRN 121901W D. R. chokin

CA Dipesh Choksi

Partner

M. NO. 128674

ICAI UDIN NO.:- 23128674BGZROY6934

Place: Surat

Date: 15/07/2023





2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja,

Surat, Gujarat- 395003

| Consolidated Profit And Loss Statement of Unaudited Fin | | | | mount In Lacs | |
|---------------------------------------------------------------------------------------|------------------------------------|----------------------------------|------------------------------------|-------------------------------------|--|
| | Quarter Ended | | | Year Ended | |
| Particulars | 30.06.2023 Unaudited (CY Q1) | 31.03.2023 Audited (PY Q4) | 30.06.2022 Unaudited (PY Q1) | 31.03.2023 Audited FY 2022-23 | |
| I. Revenue From Operations | | | | | |
| Net Sales/Income From Operations (Net of Taxes) Other Income | 864.26 32.87 | 845.83 63.68 | 597.20 0.88 | 3169.2 115.8 | |
| TOTAL INCOME | 897.14 | 909.51 | 598.08 | 3285.0 | |
| II. EXPENSES | | | | | |
| Cost of Materials Consumed Purchase of Stock-in-Trade | 407.95 | 354.64 | 272.95 | 1218.5 | |
| Changes in Inventories of Finished Goods, | 119.87 | 274.59 | 324.86 | 1092.9 | |
| Work-In-Progress and Stock-In-Trade Employment Benefit Expenses | 13.18 | -135.42 | -210.11 | -289.4 | |
| Financial Costs | 47.84 | 51.18 | 32.05 | 161.03 | |
| Depreciation and Amortization Expenses | 09.88 | 15.41 | 08.20 | 46.59 | |
| Other Expenses | 13.34 99.00 | 11.76 | 09.12 | 36.47 | |
| TOTAL EXPENSES | 711.06 | 105.79 677.96 | 90.96 528.03 | 361.06 2627.20 | |
| III. Profit Before Exceptional and Extraordinary Items and Tax IV. Exceptional Items | 186.08 | 231.55 | 70.05 | 657.82 | |
| V. Profit Before Extraordinary Items and Tax | 186.08 | 231.55 | 70.05 | · /F7 00 | |
| VI. Extraordinary Items | - | | 70.05 | 657.82 | |
| VII. Profit Before Tax VIII. Tax Expense : | 186.08 | 231.55 | 70.05 | 657.82 - | |
| (1) Current Tax | -45.78 | -4.35 | - | -54.15 | |
| (2) MAT Credit | - | - | - | - | |
| (3) Excess Tax Provision of Earlier Year | - | - | - | 49.80 | |
| (4) Deferred Tax | - | -29.43 | - 1 | -51.94 | |
| IX. Net Profit/(Loss) for the Period | 140.30 | 197.77 | 70.05 | 601.53 | |
| X. Paid Up Equity Share Capital (FV:- Rs. 10/- each) XI. Earning Per Equity Share: | 1149.92 | 1149.92 | 800.00 | 1149.92 | |
| (1) Basic- Not Annualized | 01.22 | 01.72 | 0.88 | 06.23 | |
| (2) Diluted- Not Annualized | 01.22 | 01.72 | 0.88 | 06.23 | |

For And On Behalf Of The Board
TRIDENT LIFELINE LIMITED

Place: Surat

Date: 15th July, 2023

Executive Director Hardik Desai

(DIN No: 01358227)

Whole Time Director &

CFO

Mayurkumar Gajera (DIN No: 08629139)

Notes to Financial Results

- 1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
- 2. The above Financial Results of the company for the period ended on 30th June, 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15th July, 2023.
- 3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
- 4. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TNS Pharma Pvt. Ltd. and became holding company as on 21/12/2022. Hence, we have prepared Consolidated Financials Statements of M/s. Trident Lifeline Limited as on 30/06/2023 (Quarter ended) by consolidating 51% portion of Assets and Liabilities of M/s. TNS Pharma Pvt. Ltd.





GST No.: 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

ANNEXURE-B

The details required as per Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| Particulars | M/s. DAC & CO., | Dhavl Vimal Shah |
|----------------------------|-------------------------------------------|-----------------------------|
| | Chartered Accountants | Independent Director |
| | Internal Auditor | 3980 |
| Reason for Change viz. | Appointment | Resignation |
| Appointment, Resignation, | | |
| Removal, Death or | | |
| otherwise; | | |
| Date of appointment/ | 15th July, 2023 | 15 th July, 2023 |
| cessation (as | Term: For the Financial Year 2023-24 | |
| applicable) & term of | | |
| appointment | | |
| Brief Profile (In case of | DAC & Co., a Chartered Accountancy | N.A |
| Appointment) | Firm is located at Surat engaged in | |
| | assignments such as Internal Audit, | |
| | Forensic Audit, Concurrent Audit, Stock | |
| | Audit, Indirect Taxes and many more. | |
| | Mr. Prateek Choudhary is a key partner at | 0.02 |
| | the firm, he is a fellow member of ICAI | 65 |
| | and also holds a degree in Bachelor of | |
| | Commerce. | |
| Disclosure of | NIL | NIL |
| Relationship between | | |
| Directors (In case | | |
| Appointment of Director) | | |

Pursuant to Clause 7B (ia) of Para A of Part A of Schedule III to the SEBI (LODR) Regulations, 2015:

| Sr. No. | Names of listed entities in which the resigning director holds directorships | Category of Directorship | Membership of Board Committees |
|------------|------------------------------------------------------------------------------|--------------------------|-----------------------------------|
| 1 | FLIPSTONE HOSPITALITY PRIVATE LIMITED | Director | NA |

For Trident Lifeline Limited,

Kunal Amrishbhai Chauhan Company Secretary & Compliance Officer

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2451274, 2451284 Email: info@tridentlifeline.com Web: www.tridentlifeline.com Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel: +91 261 2490224, 2490225

FINNEXURE - C

DHAVAL VIMAL SHAH

Room No. 7, Prem Milan Building, T. H. Kataria Marg, Near Zaveri Hospital, Mahim (W), Mumbai, Maharashtra-400016

Date: 15.07.2023

To,
Board of Directors,
Trident Lifeline Limited
2nd Floor, Shop-2004, North Extension,
Falsawadi Begumpura, Nodh-4/1650,
Sahara Darwaja Surat-395003.

Sub: Resignation from the post of Independent Director of the Company

I, Dhaval Vimal Shah, hereby tender my resignation from the post of an Independent Director of the Company including all the Board Committees in which I am member with immediate effect. The resignation is entirely on account of personal reason and other professional commitments and there is no other material reason other than those stated above.

Further, I want to convey sense of appreciation and feeling of gratitude for all the support I have received from all the Directors on the Board and other officers of the Company during the period of my association with the Company.

Kindly acknowledge the receipt of this Resignation Letter and arrange to complete all the formalities with regard to my Resignation including filling of forms with the office of ROC and Stock Exchange as may be required.

Thanking you,

DHAVAL VIMAL SHAH

DIN: 06366475

Peceived.



GST No.: 24AAECT8906D1ZG

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

ANNEXURE-D

<u>Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.</u>

| Sr. No. | Particulars | Details |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | Name of the target entity, details in brief such as size, turnover etc. | TLL Herbal Limited (CIN: U24299GJ2019PLC111182) is a Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat. Capital Details: Authorized Share Capital: Rs. 10,00,000/divided into 1,00,000 Equity Shares of Rs.10/each Paid-up Share Capital: Rs. 10,00,000/- divided into 1,00,000 Equity Shares of Rs.10/- each Turnover: Nil (For the Financial Year ended March 31, 2022). |
| 2 | whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | Yes, TLL Herbal Limited, a public limited company in which Mr. Mayurkumar Mansukhbhai Gajera, Mr. Shravan H Patel, Mr. Amit Bhupendra Halvawala, Mr. Tarang Nathabhai Gajera are members cum directors and Mr. Hardik Jigishkumar Desai, Mr. Mohak Gajera and Mrs. Rinkal Mayurbhai Gajera are members and all of above are part of promoters/promoters group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TLL Herbal). The transaction is being undertaken on an arm's length basis. |
| 3 | Industry to which the entity being acquired belongs | Pharmaceutical Industry |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | To expand the business towards new technologies by establishing a Research & Development cum production facility along with integration facility. |
| 5 | Brief details of any governmental or regulatory approvals required for the acquisition. | The acquisition is within the overall limit approved by the Shareholders of the Company under Section 186 of the Companies Act, 2013. |
| 6 | Indicative time period for completion of the acquisition | Approx. One Month |

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2451274, 2451284 Email: info@tridentlifeline.com Web: www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel: +91 261 2490224, 2490225



GST No.: 24AAECT8906D1ZG

| TRIDENT LIFELINE LI | MITED |
|---------------------|-------|
|---------------------|-------|

| ormerly 7rider | t Consideration _{mited)} whether cash consideration or share swap and details of the same; | Subscription of shares is by way of Cash Consideration |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8 | Cost of acquisition or the price at which the shares are acquired; | Rs 10/- per share (face value) |
| 9 | Percentage of shareholding / control acquired and / or number of shares acquired; | Pre-acquisition holding: NIL Post-acquisition holding (Proposed): 51,000 equity shares of Rs 10/- amounting of Rs. 5,10,000/- constituting 51% equity stake in TLL Herbal. |
| 10 | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | Date of incorporation: December 04, 2019 Product/line of business: Pharmaceutical Company Last 3 years' turnover: Financial Year 2019-20: NIL Financial Year 2020-21: NIL Financial Year 2021-22: NIL |
| | | Presence of entity: India |

For Trident Lifeline Limited,

Kunal Amrishbhai Chauhan Company Secretary & Compliance Officer